Rapid, point-of-need diagnostic for sexually transmitted infections
Ended Project Grant Awarded Last action
- Award ID
- R43AI157577
- Recipient
-
Godx Inc. UEI FZPKPXA6S8L8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $892,788
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Funding
-
- $595,192.00 Federal
- $297,596.00 Non-federal
- Place of performance
- Wisconsin, USA
Award details come from USAspending.gov.
Description
- Abstract
- Over 370 million people worldwide are infected with the sexually transmitted infections (stis) chlamydia, gonorrhea, and trichomoniasis each year. While treatable, delayed treatment can have serious health problems, including infertility, disseminated infection, and pregnancy complications. Since fewer than half of at-risk individuals are screened for these common stis, IT is necessary to destigmatize STI testing and bring rapid point-of-care STI diagnostics to the developed and especially to the developing world, where over 75% of STI cases are thought to occur. Current nucleic acid-based STI tests offer optimal sensitivity and specificity but require laboratory infrastructure (electricity, refrigeration, and trained laboratory technicians) that is largely lacking where these stis are most prevalent. These tests take days to return a result, which can result in loss of patient to follow-up and treatment. In addition, these tests fail to track the occurrence of antibiotic-resistant gonorrhea. With increases in azithromycin and ciprofloxacin resistance, and more frequent reports of cephalosporin resistance, multidrug- resistant gonorrhea could become a serious threat to global health, necessitating susceptibility testing and antibiotic stewardship. In this sbir project, godx, INC. Proposes to develop a rapid, hand-held, low-cost, and sensitive point-of-care diagnostic to deliver rapid STI test results, which would simplify screening and allow for immediate treatment at the initial visit. To develop a rapid test for chlamydia, gonorrhea, and trichomoniasis, we will focus on innovations to integrate nucleic acid extraction, amplification, and detection to develop and test a prototype device by the end of phase II. Our easy-to-use sample preparation device would require fewer than three user steps to purify nucleic acids for downstream detection. We will also reach benchmarks for the sensitive and specific amplification of genetic markers in neisseria gonorrhoeae, chlamydia trachomatis, and trichomonas vaginalis using an isothermal amplification technique followed by lateral flow detection. Our test will also amplify genetic predictors of antibiotic susceptibility to aid in the tracking and treatment of antibiotic resistant gonorrhea. Finally, we will integrate our assays into a test device delivering both STI and AMR test results in 30 minutes, with performance on PAR with laboratory-based STI tests. Our diagnostic tool will be simple and low-cost, making IT ideal for use in the developing world where laboratory infrastructure is lacking, affordable for better screening programs worldwide, and easy enough for eventual in-home testing.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $297,596 | $0 | |
| Original award | $297,596 | $297,596 |
Quick answers
Who received award R43AI157577?
R43AI157577 was awarded to Godx Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on April 23, 2021.
How much is award R43AI157577 worth?
$892,788 has been obligated on R43AI157577: $595,192 in federal funding and $297,596 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award